Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of neuronal action potential. [GO_REF:0000058, GOC:TermGenie, PMID:25126967]
Positive regulation of neuronal action potential is a complex biological process that involves the coordinated action of various ion channels, neurotransmitters, and intracellular signaling pathways. It refers to the mechanisms that enhance or promote the generation and propagation of action potentials, the electrical signals that travel along neurons to transmit information.
1. **Depolarization and Threshold:** The process begins with a stimulus that causes a localized depolarization of the neuron's membrane. This depolarization occurs when the membrane potential becomes less negative, moving closer to the threshold potential. The threshold potential is a critical level of depolarization that must be reached to trigger an action potential.
2. **Sodium Channel Activation:** Once the threshold potential is reached, voltage-gated sodium channels in the neuronal membrane open. These channels are highly selective for sodium ions (Na+), allowing a rapid influx of Na+ into the cell. This influx of positively charged ions further depolarizes the membrane, causing a rapid and dramatic rise in the membrane potential.
3. **Sodium Channel Inactivation:** As the membrane potential rises, sodium channels begin to inactivate. This inactivation is a crucial step in ensuring the unidirectional propagation of the action potential. It prevents the backward flow of the signal.
4. **Potassium Channel Activation:** While sodium channels are inactivating, voltage-gated potassium channels open. These channels are highly selective for potassium ions (K+), allowing an efflux of K+ out of the cell. This efflux of positively charged ions counteracts the influx of Na+, leading to a repolarization of the membrane.
5. **Repolarization:** The repolarization phase brings the membrane potential back to its resting state. This is primarily driven by the efflux of K+ through the open potassium channels.
6. **Hyperpolarization:** In some cases, the membrane potential can briefly become more negative than the resting potential, a state known as hyperpolarization. This is due to the continued efflux of K+ after the sodium channels have closed.
7. **Refractory Period:** Following an action potential, there is a brief period during which the neuron is less likely to fire another action potential. This is known as the refractory period and is important for ensuring the proper spacing and direction of action potential propagation.
8. **Neurotransmitter Release:** The arrival of an action potential at the synapse triggers the release of neurotransmitters from the presynaptic neuron. These neurotransmitters bind to receptors on the postsynaptic neuron, influencing its activity and contributing to the propagation of the signal.
9. **Intracellular Signaling:** The binding of neurotransmitters to their receptors can activate various intracellular signaling pathways. These pathways can influence the activity of ion channels, modulate gene expression, and contribute to the overall regulation of neuronal function.
10. **Modulatory Factors:** The positive regulation of neuronal action potential can be influenced by various factors, including the concentration of ions in the extracellular fluid, the presence of neuromodulators, and the activity of other neurons.
The precise mechanisms and molecular players involved in positive regulation of neuronal action potential can vary depending on the type of neuron and the specific function it serves. However, the fundamental principles outlined above provide a general framework for understanding this crucial aspect of neuronal communication.'
"
Protein | Definition | Taxonomy |
---|---|---|
Lysosomal acid glucosylceramidase | A lysosomal acid glucosylceramidase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P04062] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
ambroxol | Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride. | aromatic amine | |
beta-glucono-1,5-lactone | beta-glucono-1,5-lactone: structure D-glucono-1,5-lactone : An aldono-1,5-lactone obtained from D-gluconic acid. | aldono-1,5-lactone; gluconolactone | animal metabolite; mouse metabolite |
1-deoxynojirimycin | 1-deoxy-nojirimycin: structure in first source duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration. | 2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid | anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite |
miglustat | miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group. miglustat: a glucosylceramide synthase inhibitor | piperidines; tertiary amino compound | anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor |
n-phenylphthalimide | N-phenylphthalimide: structure given in first source | ||
N-Benzylphthalimide | isoindoles | ||
1-(10h-phenothiazin-2-yl)ethanone | 1-(10H-phenothiazin-2-yl)ethanone: structure in first source | phenothiazines | |
mor-14 | N-methyldeoxynojirimycin: glucosidase inhibitor | hydroxypiperidine; piperidine alkaloid; tertiary amino compound | anti-HIV agent; cardioprotective agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; plant metabolite |
1,2,3,4-tetrahydroxy-nor-tropane | calystegine B(2): RN given for (2-endo,3-exo,4-endo)-isomer; structure in first source | ||
homonojirimycin | homonojirimycin: inhibits alpha-glucosidase; RN given for (2R-(2alpha,3alpha,4beta,5alpha,6beta))-isomer; structure in first source | ||
cyclophellitol | cyclophellitol: structure given in first source; isolated from Phellinus sp. | ||
calystegine a3 | calystegine A3: also inhibits beta-xylosidase; structure in first source | ||
miglitol | piperidines | ||
isofagomine | piperidines | ||
n-nonyl-1-deoxynojirimycin | N-nonyldeoxynojirimycin : A hydroxypiperidine that is deoxynojirimycin (duvoglustat) in which the amino hydrogen is replaced by a nonyl group. | hydroxypiperidine; tertiary amino compound | antiviral agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; EC 3.2.1.45 (glucosylceramidase) inhibitor |
1-(1-benzimidazolyl)-3-(1-cyclohex-3-enylmethoxy)-2-propanol | benzimidazoles | ||
2-(2-phenylethylthio)-3-pyridinecarboxylic acid | aromatic carboxylic acid; pyridines | ||
4-(2-furanylmethyl)-3-(phenylmethyl)-1H-1,2,4-triazole-5-thione | benzenes | ||
2-[[4-(4-chloroanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | dialkylarylamine; tertiary amino compound | ||
4-(benzenesulfonamido)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)benzamide | sulfonamide | ||
tamoxifen | stilbenoid; tertiary amino compound | angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator | |
4-oxido-3-(4-phenoxyphenyl)-4a,5,6,7,8,8a-hexahydroquinoxalin-1-ium 1-oxide | aromatic ether | ||
2-[[4-(3-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | dialkylarylamine; tertiary amino compound | ||
N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine | N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine : A member of the class of quinazolines that is quinazoline which is substituted by a pyridin-3-yl group and a (1-benzylpiperidin-4-yl)nitrilo group at positions 2 and 4, respectively. | aromatic amine; piperidines; pyridines; quinazolines; secondary amino compound; tertiary amino compound | |
N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamide | aminoquinoline | ||
n-(5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin | |||
ogt2378 | sinbaglustat: an antineopl agent; structure in first source | ||
nnc 26-9100 | NNC 26-9100: structure in first source | aminopyridine | |
2-[[4-[2-[(2-methylpropan-2-yl)oxy]anilino]-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether | ||
2-[[4-(5-chloro-2-methoxyanilino)-6-(1-piperidinyl)-1,3,5-triazin-2-yl]amino]ethanol | methoxybenzenes; substituted aniline | ||
2-[[4-(4-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | dialkylarylamine; tertiary amino compound | ||
2-[[4-(2-chloroanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | dialkylarylamine; tertiary amino compound | ||
2-[[4-(2-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | methoxybenzenes; substituted aniline | ||
2-[[4-(3-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | methoxybenzenes; substituted aniline | ||
2-[[4-(4-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | methoxybenzenes; substituted aniline | ||
2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenol | dialkylarylamine; tertiary amino compound | ||
2-[[4-(2-phenoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether | ||
2-[[4-(1-pyrrolidinyl)-6-[2-(trifluoromethoxy)anilino]-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether | ||
2-[[4-(5-chloro-2-ethoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether | ||
2-[[4-(5-chloro-2-propan-2-yloxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether |